Advertisement
Screener

Shattuck Labs, Inc. (STTK) ROE

Shattuck Labs, Inc. ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Shattuck Labs, Inc. roe for the quarter ending 2026-06-30 was -24.90%, a change of 82.99% year-over-year.
  • Shattuck Labs, Inc. roe for the quarter ending 2026-03-31 was -52.04%, a change of 52.43% year-over-year.
  • Shattuck Labs, Inc. roe for the quarter ending 2025-12-31 was -59.24%, a change of 35.46% year-over-year.
  • Shattuck Labs, Inc. roe for the quarter ending 2025-09-30 was -58.87%, a change of 18.18% year-over-year.
  • Shattuck Labs, Inc. roe for fiscal 2025 was -59.24%, a change of 35.46% from fiscal 2024.
  • Shattuck Labs, Inc. roe for fiscal 2024 was -94.71%, a change of -34.38% from fiscal 2023.
  • Shattuck Labs, Inc. roe for fiscal 2023 was -60.33%, a change of -2.46% from fiscal 2022.
  • Shattuck Labs, Inc. roe for fiscal 2022 was -57.87%, a change of -41.32% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-24.90%-$52.57M-$15.15M$211.14M
2026-03-31-52.04%-$49.87M-$14.77M$95.84M
2025-12-31-59.24%-$48.81M-$12.59M$82.39M
2025-09-30-58.87%-$54.9M-$10.06M$93.24M
2025-06-30-107.88%-$61.51M-$12.46M$57.02M
2025-03-31-104.47%-$70.61M-$13.70M$67.59M
2024-12-31-94.71%-$75.41M-$18.68M$79.63M
2024-09-30-77.06%-$74.42M-$16.68M$96.58M
2024-06-30-77.10%-$85.28M-$21.55M$110.62M
2024-03-31-66.05%-$85.08M-$18.50M$128.81M
2023-12-31-60.33%-$87.3M-$17.69M$144.71M
2023-09-30-84.25%-$95.02M-$27.54M$112.78M
2023-06-30-66.53%-$92.12M-$21.35M$138.46M
2023-03-31-62.25%-$98.14M-$20.72M$157.65M
2022-12-31-57.87%-$101.95M-$25.41M$176.16M
2022-09-30-34.44%-$68.69M-$24.64M$199.42M
2022-06-30-27.62%-$61.46M-$27.37M$222.53M
2022-03-31-23.17%-$57.69M-$24.53M$248.94M
2021-12-31-16.55%-$44.97M$7.85M$271.79M
2021-09-30-24.82%-$64.83M-$17.41M$261.17M
2021-06-30-21.38%-$59.25M-$23.60M$277.09M
2021-03-31-14.02%-$41.86M-$11.81M$298.66M
2020-12-31-11.81%-$36.6M-$12.01M$309.86M
2020-09-3054.76%-$31.96M-$11.83M-$58.36M
2020-06-3058.28%-$27.41M-$6.21M-$47.03M
2020-03-3166.29%-$27.09M-$6.55M-$40.86M
2019-12-3169.42%-$23.98M-$7.37M-$34.55M

Annual ROE

DateROENet income 12 monthShareholder equity
2025-12-31-59.24%-$48.81M$82.39M
2024-12-31-94.71%-$75.41M$79.63M
2023-12-31-60.33%-$87.3M$144.71M
2022-12-31-57.87%-$101.95M$176.16M
2021-12-31-16.55%-$44.97M$271.79M
2020-12-31-11.81%-$36.6M$309.86M
2019-12-3169.42%-$23.98M-$34.55M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03